Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 239 results for headache

  1. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA682

  2. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.

    Highly specialised technologies guidance
    Published
    28 January 2015
    View recommendations

    Sections for HST1

  3. Deep brain stimulation for intractable trigeminal autonomic cephalalgias (HTG252)

    Evidence-based recommendations on deep brain stimulation for intractable trigeminal autonomic cephalalgias. This involves delivering electrical impulses to a precise area of the brain using an electrode to mask the pain.

    HealthTech guidance
    Published
    23 March 2011
    View recommendations

    Sections for HTG252

  4. NICE encourages further research on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. Studies should describe whether the procedure is used for treatment or prevention, and whether it is used for cluster headache or migraine. Clinicians should clearly document details of patient selection and the treatment regimen. Outcome measures should include changes in the number and severity of cluster headache or migraine episodes, medication use, quality of life in the short and long term, side effects, acceptability, and device  durability. NICE may update this guidance on publication of further evidence.

    transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. Studies should describe whether...

    Research recommendation
    Published
    6 April 2016

  5. NICE encourages further research on sphenopalatine ganglion stimulation for chronic cluster headache. Reported outcomes should include long-term efficacy and device durability.

    further research on sphenopalatine ganglion stimulation for chronic cluster headache. Reported outcomes should include long-term...

    Research recommendation
    Published
    6 October 2015

  6. Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)

    Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).

    Technology appraisal guidance
    Published
    23 January 2001
    View recommendations

    Sections for TA20

  7. Middle meningeal artery embolisation for non-acute subdural haematomas

    In development Reference number: GID-HTG10869 Expected publication date:  19 November 2026

    HealthTech guidance
    In development

  8. Migalastat for treating Fabry disease (HST4)

    Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.

    Highly specialised technologies guidance
    Published
    22 February 2017
    View recommendations

    Sections for HST4

  9. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

    Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

    Technology appraisal guidance
    Last updated
    3 March 2016
    View recommendations

    Sections for TA23

  10. Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

    Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    6 October 2015

  11. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

    Evidence summary
    Published
    25 March 2014

  12. Percutaneous closure of patent foramen ovale for recurrent migraine (HTG242)

    Evidence-based recommendations on percutaneous closure of patent foramen ovale for recurrent migraine. This involves passing a device through a large vessel in the groin up into the heart and closing/blocking the hole in the wall of the heart.

    HealthTech guidance
    Published
    15 December 2010
    View recommendations

    Sections for HTG242

  13. Eliglustat for treating type 1 Gaucher disease (HST5)

    Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults.

    Highly specialised technologies guidance
    Published
    28 June 2017
    View recommendations

    Sections for HST5

  14. Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

    Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.

    Technology appraisal guidance
    Published
    26 November 2014
    View recommendations

    Sections for TA323

  15. Lumbar infusion test for the investigation of normal pressure hydrocephalus (HTG169)

    Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.

    HealthTech guidance
    Published
    25 June 2008
    View recommendations

    Sections for HTG169